Heterogeneity in Combined Immunodeficiencies with Associated Or Syndromic Features (Review)
Total Page:16
File Type:pdf, Size:1020Kb
EXPERIMENTAL AND THERAPEUTIC MEDICINE 21: 84, 2021 Heterogeneity in combined immunodeficiencies with associated or syndromic features (Review) LAVINIA CABA1*, CRISTINA GUG2* and EUSEBIU VLAD GORDUZA1,3* 1Department of Medical Genetics, ‘Grigore T. Popa’ University of Medicine and Pharmacy, 700115 Iași; 2Department of Microscopic Morphology, ‘Victor Babeş’ University of Medicine and Pharmacy, 300041 Timisoara; 3Prenatal Diagnosis Department, ‘Cuza Voda’ Obstetrics‑Gynecology Clinical Hospital, 700038 Iași, Romania Received September 14, 2020; Accepted October 14, 2020 DOI: 10.3892/etm.2020.9517 Abstract. Primary immunodeficiencies are genetic diseases, current medical practice, but also for the theoretical value of mainly monogenic, that affect various components of the improving biological and biomedical applications. immune system and stages of the immune response. The category of combined immunodeficiencies with associated or syndromic features comprises over 70 clinical entities, char- Contents acterized by heterogeneity of clinical presentation, mode of transmission, molecular, biological, mutational and immuno- 1. Introduction logical aspects. The mutational spectrum is wide, ranging from 2. Molecular heterogeneity and biological processes structural chromosomal abnormalities to gene mutations. The 3. Mutational heterogeneity impact on the function of the proteins encoded by the genes 4. Clinical heterogeneity and mode of inheritance involved is different; loss of function is most common, but situ- 5. Conclusions ations with gain of function are also described. Most proteins have multiple functions and are components of several protein interaction networks. The pathophysiological mechanisms 1. Introduction mainly involve: Missing enzymes, absent or non‑functional proteins, abnormal DNA repair pathways, altered signal transduction, developmental arrest in immune differentiation, Primary immunodeficiencies (PIDs) are rare, mostly mono- impairment of cell‑to‑cell and intracellular communications. genic genetic diseases that affect various components of the Allelic heterogeneity, reduced penetrance and variable expres- immune system and are characterized by pathological, clinical, sivity are genetic phenomena that cause diagnostic difficulties, and immunological diversity (1,2). The prevalence of PIDs is especially since most are rare/very rare diseases, which is approximately 4‑10 per 105 live births (3). equivalent to delaying proper case management. Most primary The International Union of Immunological Societies immunodeficiencies are Mendelian diseases with X‑linked (IUIS) recognizes the existence of 430 entities and 408 or recessive inheritance, and molecular diagnosis allows the different genes involved. It classifies diseases into 9 catego- identification of family members at risk and the application ries: Immunodeficiencies affecting cellular and humoral of appropriate primary and secondary prevention measures immunity, combined immunodeficiencies with associated in addition to the specific curative ones. In conclusion, recog- or syndromic features, predominantly antibody deficien- nizing heterogeneity and its sources is extremely important for cies, diseases of immune dysregulation, congenital defects of phagocyte number or function, defects in intrinsic and innate immunity, autoinflammatory disorders, comple- ment deficiencies and phenocopies of inborn errors of immunity (4‑6). Of these, combined immunodeficien- Correspondence to: Professor Eusebiu Vlad Gorduza, Department cies with associated or syndromic features present high of Medical Genetics, ‘Grigore T. Popa’ University of Medicine and heterogeneity manifested at the molecular and muta- Pharmacy, 16 Universitatii Street, 700115 Iași, Romania tional level. Biological processes involve different gene E‑mail: [email protected] expression products, ‘extraimmune’ clinical symptoms *Contributed equally characteristic of each syndrome, and many diseases present incomplete penetrance and variable expressivity. This Key words: combined immunodeficiencies, molecular hetero‑ combined immunodeficiencies are classified into 10 types: geneity, gene mutations, abnormal molecular pathways, clinical Immunodeficiency with congenital thrombocytopenia; heterogeneity DNA repair defects (immunodeficiencies affecting cellular and humoral immunity); thymic defects with additional congenital anomalies; immuno‑osseous dysplasias; hyper 2 CABA et al: HETEROGENEITY IN COMBINED IMMUNODEFICIENCIES IgE syndromes (hyperimmunoglobulin E syndromes or The functions of telomeres are regulated by other genes HIES); dyskeratosis congenita (DKC), myelodysplasia, short that influence telomeric DNA binding TERT,( TINF2, STN1 telomeres; defects of vitamin B12 and folate metabolism; and CTC1), telomerase RNA binding (DKC1, NHP2, NOP10, ectodermal anhidrotic dysplasia with immunodeficiency TERT, PARN and WRAP53) or telomerase activity (TERT and (EDA‑ID); and calcium channel defects (4). DKC1) (23). Correct and early diagnosis is necessary to prevent compli- In addition, in immunodeficiencies different enzymatic cations and reduce mortality (7). The molecular diagnosis can activity may be disturbed: GTPase regulator activity (WAS), be followed by early protective and curative interventions, but small GTPase binding (WAS), phospholipase binding (WAS), also by avoiding the usual interventions which in the case of protein kinase binding (WAS, ERCC6L2, STAT3, PARN and certain PIDs can bring additional complications (for example IKBKB), DNA‑dependent protein kinase activity (ATM), heli- use of DNA‑radiomimetic drugs in radiosensitive PIDs) (8). case (BLM , HELLS, MCM4, ERCC6L2, CHD7, SMARCAL1, It is estimated that 70‑90% of patients with PID remain undi- RTEL1, SKIV2L), hydrolase (HELLS, PMS2, MCM4, POLE, agnosed worldwide (9). The onset can be at any age, but early ERCC6L2, CHD7, SMARCAL1, MYSM1, RTEL1, TPP1, onset correlates negatively with the severity of the manifesta- DCLRE1B/SNM1/APOLLO, PARN and MTHFD1), nuclease tions (7). In many cases, patients are consulted for recurrent (PMS2, POLE, DCLRE1B/SNM1/APOLLO and PARN), infections, but the etiological diagnosis is delayed. There are metalloprotease (MYSM1), phosphoglucomutase activity studies that show that in the US the etiological diagnosis is (PGM3), DNA polymerase binding (RTEL1) (23). delayed by up to 12.4 years (10). During all this time, negative Another process that is perturbed in immunodeficiencies is consequences can appear in personal, social and professional ion binding and the main genes implied are TGFBR1, TGFBR2, life, so that the quality of life is profoundly altered (3,7,11). In ZNF341, DNMT3B, ZBTB24, RNF168, LIG1, MYSM1, EXTL3, some cases, patients also have a predisposition to autoimmune RTEL1, TERT, TPP1, PARN, TCN2, IKBKG (NEMO), SP110, diseases, autoinflammatory diseases or lymphoproliferative HOIL1 (RBCK1), RNF31, KMT2D (MLL2), KMT2D (MLL2), phenomena (4,8,12‑16). KDM6A, BCL11B, STIM1, FAT4 and CCBE1 (23). The connection with RNA could be abnormal in immuno- 2. Molecular heterogeneity and biological processes deficiencies because of an abnormal ribonucleoprotein DKC1,( NHP2, NOP10, TERT), RNA binding (DKC1, NHP2, NOP10 The vast majority of genes involved are genes that encode and WRAP53) or box H/ACA snoRNA binding (DKC1, NHP2 proteins. In combined immunodeficiencies with syndromic and NOP10) (23). features a double heterogeneity is present: A specific protein Other processes are disturbed because of gene muta- presents multiple and diverse molecular functions while tions implied in protein binding (WAS, ATM, BLM, STAT3, several different proteins have the same molecular func- TERT, IKBKB, WRAP53, IKBKG (NEMO), NFKBIA, tion. Table I summarizes the molecular functions of these ORAI1, STIM1, PNP, HOIL1, KDM6A,KMT2A and IL6ST), proteins and the biological processes in which they intervene Rac GTPase (WAS), SH3 domain binding (WAS, WIPF1), according to UniProt Knowledgebase https://www.uniprot. profilin binding WIPF1( ), ATP binding [IKBKB, TGFBR1, org/ (4‑6,17‑23). TGFBR2, ATM, BLM (RECQL3), HELLS, PMS2, MCM4, Some genes encode proteins that interact with chromatin, LIG1, ERCC6L2,SKIV2L, CHD7, SMARCAL1, RTEL1 and being implied in chromatin binding (DNMT3B, RNF168, MTHFD1], chaperone binding (TERT and WRAP53), actin POLE, STAT5B and KDM6A), chromatin DNA binding (actin filament) binding WAS,( WIPF1 and ARPC1B) (23). (STAT3, KDM6A) or chromatin regulation (CHD7, M YSM1, Other genes, such as RMRP, RNU4ATAC or TERC, encode KMT2D and KDM6A) (23). noncoding RNA (part of RNase MRP), small nuclear RNA Other proteins interact with histones and allow histone and telomerase RNA component (Table I). Mutations in these binding (RNF168, MYSM1, WRAP53 and KMT2D), histone genes cause alterations in processing of ribosomal RNA. deacetylase binding (DNMT3B), histone demethylase activity RMRP gene mutations disturb mitochondrial DNA replication [H3‑K27 specific] (KDM6A) or histone methyltransferase and cell cycle control. RNU4ATAC gene mutations produce activity [H3‑K4 specific] KMT2D( and KMT2A) (23). defects of spliceosome complex. Mutations in the TERC gene A major category is represented by genes that encode are implied in dysfunctions of telomere length (19,22,24‑26). proteins implied in interaction with DNA: DNA binding Genes including HELLS, TBX1, SEMA3E, FOXN1, (ZNF341, ATM, BLM, NFE2L2, DNMT3B, PMS2, POLE, CCBE1 or KDM6A encode proteins involved in development POLE2, LIG1, ERCC6L2, TBX1, CHD7, FOXN1, MYSM1, of one or more organs. The